Provided by Tiger Trade Technology Pte. Ltd.

Travere Therapeutics, Inc.

66.28
+0.61000.93%
Pre-market: 66.09-0.1900-0.29%06:54 EDT
Volume:1.89M
Turnover:124.40M
Market Cap:6.25B
PE:-139.11
High:66.70
Open:65.70
Low:65.07
Close:65.67
52wk High:67.85
52wk Low:17.27
Shares:94.26M
Float Shares:92.77M
Volume Ratio:1.73
T/O Rate:2.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4764
EPS(LYR):-0.2864
ROE:-236.35%
ROA:-3.73%
PB:254.78
PE(LYR):-231.46

Loading ...

Travere Therapeutics Announces Full FDA Approval of Filspari® (Sparsentan), the First and Only Approved Medicine for Fsgs

THOMSON REUTERS
·
Apr 14

Travere Therapeutics:Filspari Indicated to Reduce Proteinuria in Adults & Children Aged 8 Years & Older With Fsgs Who Do Not Have Nephrotic Syndrome

THOMSON REUTERS
·
Apr 14

Travere Therapeutics Inc - Filspari Indication Expands Addressable Population to Over 100,000 in U.S.

THOMSON REUTERS
·
Apr 14

Travere Therapeutics Inc - Filspari Available Only Through Filspari Rems Program

THOMSON REUTERS
·
Apr 14

Travere Therapeutics trading halted, news pending

TIPRANKS
·
Apr 14

NASDAQ TRADE HALT HALT NEWS PENDING AT 05:33 PM

Reuters
·
Apr 14

Travere Therapeutics (TVTX) Receives a Buy from Guggenheim

TIPRANKS
·
Apr 09

Travere director Roy D. Baynes disposes of Travere Therapeutics shares worth $330,000

Reuters
·
Apr 08

Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF) and Travere Therapeutics (TVTX)

TIPRANKS
·
Apr 07

Travere Therapeutics announces annual shareholder meeting

Reuters
·
Apr 07

Travere Therapeutics rises 9.5%

TIPRANKS
·
Apr 06

Travere CEO Eric Dube disposes of TVTX shares worth $1.86 million

Reuters
·
Apr 03

Travere Chief Legal Officer Elizabeth Reed disposes of TVTX shares worth $0.3 million

Reuters
·
Apr 03

Travere Therapeutics (TVTX) Is Up 14.0% After FDA Focus Shifts To FILSPARI FSGS Label Expansion - Has The Bull Case Changed?

Simply Wall St.
·
Apr 02

A Look At Travere Therapeutics (TVTX) Valuation After Recent Share Price Pullback

Simply Wall St.
·
Mar 30

J.P. Morgan Gives a Buy Rating to Travere Therapeutics (TVTX)

TIPRANKS
·
Mar 25

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Insmed (INSM) and Travere Therapeutics (TVTX)

TIPRANKS
·
Mar 24

Citi opens ‘upside 90-day catalyst watch’ on Travere Therapeutics

TIPRANKS
·
Mar 24

A Look At Travere Therapeutics (TVTX) Valuation After Recent Share Price Volatility

Simply Wall St.
·
Mar 22

Is Travere Therapeutics (TVTX) Pricing Signal An Opportunity After Recent Share Price Pullback?

Simply Wall St.
·
Mar 20